论文部分内容阅读
目的探讨培美曲赛联合顺铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法选择70例患者,分为PEM组、GP组各35例,分别接受培美曲赛联合顺铂与吉西他滨联合顺铂治疗。PEM组给予PEM 500mg/m2,d1,DDP 75mg/m2,d1、d2、d3;GP组给与GEM 1000mg/m2,d1、d8,DDP 75mg/m2,d1、d2、d3;21d为1个周期,2个周期后评价疗效。结果 PEM组近期有效率为37.14%,GP组近期有效率为31.43%,组间差异无统计学意义(P>0.05);血液毒性PEM组低于GP组(P<0.05),差异有统计学意义。结论培美曲赛联合顺铂治疗晚期非小细胞肺癌近期疗效不劣于吉西他滨联合顺铂,但在不良反应方面PEM组发生率明显减低,耐受性好,值得临床应用。
Objective To investigate the curative effect and toxicity of pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods Seventy patients were divided into PEM group and 35 patients in GP group. Pemetrexed combined with cisplatin and gemcitabine combined with cisplatin were given respectively. PEM group was given PEM 500mg / m2, d1, DDP 75mg / m2, d1, d2, d3; GP group given GEM1000mg / m2, d1, d8, DDP 75mg / m2, d1, d2, d3; After 2 cycles evaluation of efficacy. Results The effective rate was 37.14% in PEM group and 31.43% in GP group. There was no significant difference between the two groups (P> 0.05). The hematotoxicity in PEM group was lower than that in GP group (P <0.05) significance. Conclusion Pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer is not inferior to gemcitabine plus cisplatin in the short term. However, the incidence of adverse reactions in PEM group is significantly reduced and well tolerated, which is worthy of clinical application.